MaxWell Biosciences
Developing an entirely new class of patented, virucidal, small molecule drugs.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
* | $3.0m | Grant | |
| Total Funding | 000k | ||
Related Content
Maxwell Biosciences is a biotechnology company focused on developing next-generation virucidal drugs that irreversibly deactivate human herpes virus and pandemic pathogens. The company operates in the pharmaceutical and healthcare market, primarily serving medical institutions, research organizations, and healthcare providers. Maxwell's business model revolves around the research, development, and commercialization of small molecule drugs designed to mimic the antiviral properties of natural antimicrobial peptides. These drugs target and deactivate viral DNA, RNA, and proteins, offering a novel approach to antiviral treatment. The company generates revenue through partnerships, licensing agreements, and potential future sales of its therapeutic products. Currently, Maxwell is advancing its lead candidate, MXB 005, targeting Herpes cold sores, and is in the lead generation stage for an inhaled therapeutic for SARS CoV 2. The company collaborates with large institutional partners and benefits from government-funded research to validate its drug efficacy and safety.
Keywords: virucidal drugs, herpes virus, pandemic pathogens, antiviral treatment, small molecule drugs, antimicrobial peptides, healthcare, pharmaceutical, research, biotechnology.